Xiao Ying Meng
Direktor/Vorstandsmitglied bei BMC MEDICAL CO., LTD.
Profil
Xiao Ying Meng is currently the Director at BMC Medical Co. Ltd.
since 2019 and the Non-Executive Director at TYK Medicines, Inc. since 2021.
Previously, she worked as a Member-Supervisory Board at Chengdu Bright Eye Hospital Co., Ltd.
from 2018 to 2022.
Dr. Meng holds a doctorate degree from The Pennsylvania State University, an undergraduate degree from Nanjing University, and a graduate degree from Nanjing University.
Aktive Positionen von Xiao Ying Meng
| Unternehmen | Position | Beginn |
|---|---|---|
| BMC MEDICAL CO., LTD. | Direktor/Vorstandsmitglied | 01.12.2019 |
TYK Medicines, Inc.
 TYK Medicines, Inc. Pharmaceuticals: MajorHealth Technology TYK Medicines, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the business of research, development and commercialization of pharmaceutical products and differentiated targeted therapies to address unmet medical needs in cancer treatment. The company was founded by Wu Yusheng on November 2, 2017 and is headquartered in Huzhou, China. | Direktor/Vorstandsmitglied | 01.01.2021 |
Ehemalige bekannte Positionen von Xiao Ying Meng
| Unternehmen | Position | Ende |
|---|---|---|
| CHENGDU BRIGHT EYE HOSPITAL CO., LTD. | Direktor/Vorstandsmitglied | 10.10.2022 |
Ausbildung von Xiao Ying Meng
| Nanjing University | Undergraduate Degree |
| The Pennsylvania State University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| CHENGDU BRIGHT EYE HOSPITAL CO., LTD. | Health Services |
| BMC MEDICAL CO., LTD. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
TYK Medicines, Inc.
TYK Medicines, Inc. Pharmaceuticals: MajorHealth Technology TYK Medicines, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the business of research, development and commercialization of pharmaceutical products and differentiated targeted therapies to address unmet medical needs in cancer treatment. The company was founded by Wu Yusheng on November 2, 2017 and is headquartered in Huzhou, China. | Health Technology |
